HUTCHMED launches global Phase I trial of HMPL-A830 in solid tumors
HCM•HUTCHMED launched the Phase Ia segment of a global first-in-human study of HMPL-A830 in advanced solid tumors. The first patient was dosed in China on Sept. 24, 2026; the study will assess safety and preliminary efficacy and set an expansion dose for selected tumor types.
1. Trial begins
HUTCHMED launched the Phase Ia segment of a global first-in-human study of its HMPL-A830 KRAS-EGFR antibody-drug conjugate in advanced solid tumors. The first patient was dosed in China on Sept. 24, 2026.
2. Study and licensing
The study will generate early safety and preliminary efficacy readouts and set an expansion dose for selected tumor types. The program aims to deliver tumor-targeted KRAS inhibition while blocking EGFR signaling, seeking more durable activity with improved tolerability. GSK holds rights outside Greater China under a Sept. 3, 2026 license, while HUTCHMED is running global Phase I development.
